The global vasculitis drug market is projected to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in January 2022the European Commission approved Tavneos in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, according to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). The approval is in line with expectations and follows the FDA’s approval of Tavneos for the same indication in October 2021. Tavneos will be approved for sale in all European Union member states, as well as Iceland, Liechtenstein, and Norway.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/vasculitis-drug-market
The EU approval is based on a comprehensive development programme that culminated in the results of the pivotal phase-III trial ADVOCATE, which compared treatment regimens including Tavneos to current standard of care treatment regimens with high dose glucocorticoid use in 331 patients with ANCA-associated vasculitis in 20 countries. The Birmingham Vasculitis Activity Score was used to determine whether the research fulfilled its primary goals of disease remission at week 26 and sustained remission at week 52. (BVAS). At week 52, Tavneos was found to be superior to the standard of care.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Drug Class
o By Disease Type
o By End-Use
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including GlaxoSmithKline plc, F. Hoffmann-La Roche AG, and Novartis International AG, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Vasculitis Drug Market Report Segment
By Drug Class
- Corticosteroids,
- Immunosuppressants, and
- Biologics
By End-Use
- Hospitals
- Medical Clinic
- Other
By Disease Type
- Small Vessel,
- Large Vessel,
- Medium Vessel
A full report of Vasculitis Drug Market is available at: https://www.omrglobal.com/industry-reports/vasculitis-drug-market
Vasculitis Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Co.
- ChemoCentryx, Inc.
- Celltrion Healthcare Co. Ltd.
- Johnson & Johnson Service Co.
- Merck & Co., Inc.
- Mentor Worldwide LLC
- Teva Pharmaceuticals
- Sun Pharma
- Sanofi SA
- Pfizer
